Q-omics provides the consensus-scored F12 profile across patient tissues and cancer cell-line models. F12 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, F12 is differentially expressed in 18, with the highest sampling consensus in KIRC. Additionally, F12 protein abundance shows 21,598 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, KIRC, and BRCA as cancer lineages where F12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for F12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes F12 survival associations across molecular data types. F12 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible F12 RNA expression–survival associations across cancer types. High F12 expression shows unfavorable associations in ACC, UVM, MESO, THCA, UCS and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for F12 RNA expression.
This table summarizes F12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for F12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. F12 shows higher tumor expression in KIRC, COAD, KIRP, LUAD, THCA and HNSC. The KIRC box plot shows higher F12 RNA expression in tumor versus normal tissue (log2 FC = +1.187, t-test p < 0.001).
This table shows molecular features associated with F12 in patient tissues and cancer cell lines. In patient samples, F12 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, F12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
